CANY
SPRY icon

Caxton Associates (New York)’s ARS Pharmaceuticals SPRY Stock Holding History

Caxton Associates (New York)’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-43,169
Closed -$281K – 643
2023
Q1 		$281K Buy
43,169
+28,337
+191% +$218K 0.04% 365
2022
Q4 		$127K Buy
+14,832
New +$96.2K 0.01% 411

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Associates (New York)'s SPRY Position: Q2 2023 in Review

Caxton Associates (New York) sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 43,169 shares — an estimated $281K sold.

Caxton Associates (New York) first reported a position in SPRY in Q4 2022 and held it in 2 quarters. The position peaked at $281K in Q1 2023. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

  • Caxton Associates (New York) reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 43,169 ARS Pharmaceuticals shares in Q2 2023, an estimated $281K.
  • Caxton Associates (New York) first reported a position in ARS Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s ARS Pharmaceuticals position peaked at $281K in Q1 2023.
  • 92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.